Literature DB >> 6725504

Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment.

R S Weinstein, G F Bryce, L J Sappington, D W King, B B Gallagher.   

Abstract

Alterations in vitamin D metabolism are generally thought to account for the hypocalcemia and osteopenia caused by long term treatment with anticonvulsant drugs. Regional variation in the incidence and severity of anticonvulsant drug-induced bone disease has been attributed to differences in sunlight exposure, with most reports coming from areas with limited sunshine or from institutionalized patients. Serum ionized calcium levels in 109 ambulatory adult epileptic outpatients receiving chronic anticonvulsant drug therapy in Georgia were decreased [4.73 +/- 0.02 (+/-SE) vs. 4.97 +/- 0.01 mg/dl; P less than 0.001). Immunoreactive PTH concentrations were increased (5.5 +/- 0.4 vs. 4.0 +/- 0.3 microliterEq /ml; P less than 0.005), while bone mineral content was reduced, averaging only 88.8% of the predicted normal values. Hypocalcemia and osteopenia occurred in spite of normal mean levels of serum 25-hydroxyvitamin D and 1,25-dihydroxy-vitamin D. The indirect relationship between serum concentrations of antiepileptic drugs and the serum ionized calcium level, and the lack of correlation with vitamin D metabolite levels suggested that hypocalcemia was independent of the effect of the drugs on vitamin D metabolism. Bone biopsies revealed increased osteoid but normal calcification front formation, accelerated mineralization rate, and decreased mineralization lag time indicative of increased skeletal turnover, rather than osteomalacia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6725504     DOI: 10.1210/jcem-58-6-1003

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

Review 1.  Drug-induced rheumatic disorders: incidence, prevention and management.

Authors:  P Vergne; P Bertin; C Bonnet; C Scotto; R Trèves
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

2.  The Association Between Antiepileptic Drugs and Bone Disease.

Authors:  Alison M. Pack
Journal:  Epilepsy Curr       Date:  2003-05       Impact factor: 7.500

3.  Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.

Authors: 
Journal:  CMAJ       Date:  1996-10-15       Impact factor: 8.262

4.  Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis.

Authors:  R S Weinstein; R L Harris
Journal:  Calcif Tissue Int       Date:  1990-06       Impact factor: 4.333

5.  Multiple immunoreactive forms of osteocalcin in uremic serum.

Authors:  C M Gundberg; R S Weinstein
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  Women and epilepsy.

Authors:  Sunila E O'Connor; Mary L Zupanc
Journal:  J Pediatr Pharmacol Ther       Date:  2009-10

7.  Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy.

Authors:  Alison M Pack; Martha J Morrell; Robert Marcus; Leah Holloway; Edith Flaster; Silvia Doñe; Alison Randall; Cairn Seale; Elizabeth Shane
Journal:  Ann Neurol       Date:  2005-02       Impact factor: 10.422

Review 8.  Osteoporosis Associated with Epilepsy and the Use of Anti-Epileptics-a Review.

Authors:  Sandra J Petty; Helen Wilding; John D Wark
Journal:  Curr Osteoporos Rep       Date:  2016-04       Impact factor: 5.096

9.  Antiepileptics and bone health.

Authors:  Christian Meier; Marius E Kraenzlin
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-10       Impact factor: 5.346

10.  Secondary hyperparathyroidism and osteopenia in women following gastric exclusion surgery for obesity.

Authors:  J L Shaker; A J Norton; M F Woods; M D Fallon; J W Findling
Journal:  Osteoporos Int       Date:  1991-06       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.